The ω-3 and ω-6 polyunsaturated fats are the most common polyunsaturated fats. They play an indispensable role in maintaining the normal physiological metabolism of the human body and are essential fatty acids for the human body. ω-3 PUFAs mainly include: Alpha linolenic acid (ALA) and eicosapentaenoic acid (EPA); ω-6 PUFAs mainly include: linoleic acid (LA) and arachidonic acid (AA). The conversion and utilization of ω-3 PUFAs and ω-6 PUFAs in the human body is a complex process: Cyclooxygenase can promote the conversion of AA and EPA into prostaglandin, thromboxane A (TXA) and other products [17]. Recent studies have shown that, ω-3 PUFAs have an inhibitory effect on the occurrence and progression of malignant tumors, while ω-6 PUFAs have a promoting effect; their mechanism of action may be related to the regulation of cyclooxygenase and prostaglandin synthetase (PGES), the main enzymes in the function and reaction of prostaglandin E3, and prostaglandin E2, metabolites of ω-3 PUFAs and ω-6 PUFAs [18, 19]. ω-6 PUFAs bind to COX-2 in the human body to generate PGE2, while PGE2 can induce cell proliferation and stimulate the expression of BLC-2 protein (BLC-2 protein inhibits apoptosis) to imbalance cell proliferation and apoptosis and promote the occurrence of tumors; PGE2 can also promote extracellular matrix degradation and produce thromboxane to promote platelet aggregation, which is conducive to the invasion and metastasis of cancer cells. While ω-3 PUFAs produce PGE3 after binding to COX-1, PGE3 can inhibit the production of PGE2, and can inhibit phospholipase A2 (PLA2), phosphatidylinositol-specific phospholipase C (PI-PLC), nuclear factor-κB and COX-2 activities, which in turn reduce the proliferation and invasion of tumor cells and play a role in inhibiting the growth and metastasis of malignant tumors [20–24].
Previously, we retrospectively analyzed the clinical data of 115 patients with radical resection of colorectal cancer and found that the positive rate of prostaglandin E2 expression in colorectal cancer tissues was 87.8%, which was significantly higher than that in normal colorectal mucosal tissues, and correlated with the depth of invasion, lymph node and liver metastasis of colorectal cancer; it was positively correlated with the expression of cyclooxygenase 2; the 5-year cumulative survival rate was 63.6% in patients with double negative PGE2 and COX-2, and 37.8% in patients with double positive expression [25]. Thus, PGE2 and COX-2 downstream of ω-6 PUFAs can be used as important markers for clinical evaluation of metastasis of colorectal cancer and are important for patient prognosis assessment.
ω-6 PUFAs rely on the catalytic effect of COX-2 to generate PGE2 in the body, which can stimulate the expression of Bcl-2 protein to imbalance cell proliferation and apoptosis and thus promote tumor progression. PGE2 can also enhance the degradation of extracellular matrix, which further promotes the invasion and metastasis of cancer cells [19]. ω-6 PUFAs in the microenvironment can up-regulate PGE2 production in colorectal cancer cells and promote the transformation of myeloid-inhibiting cells (MDSC) into M2 macrophages [26]; hypoxia-inducible factor-1α (HIF-1α) secreted by M2 macrophages promotes tumor invasion and metastasis by inducing the expression of COX-2 and PGE2 in stromal cells and tumor cells in the hypoxic microenvironment [27]. HIF-1α derived from M2 macrophages elevates the secretion of CXCR4 in cancer cells to promote colorectal liver metastasis [28]. While ω-3 PUFAs produce prostaglandin E3 (PGE3) in response to COX-1, PGE3 inhibits the proliferation and invasion of tumor cells by down-regulating the expression of phospholipase A2 phosphatidylinositol-specific phospholipase C (PI-PLC), nuclear factor (NF-κB) and COX-2; PGE3 can also inhibit the metastasis of colorectal cancer by down-regulating colorectal cell adhesion factors and the formation of new blood vessels, and ω-3 PUFAs upstream of PGE3 have potential application value in the treatment of colorectal cancer as a target of anti-tumor angiogenesis [29, 30].
On the basis of previous studies, this experiment focused on exploring the role of ω-3, ω-6, PGE2, and PGE3 in gastric cancer metastasis, and the results showed that, the expression of PGE2 and COX-2 in gastric cancer cell lines was closely related to their liver metastasis, that is, PGE2 and COX-2 were expressed in cell lines MKN45 and MKN74 with high liver metastasis, while PGE3 and COX-1 were expressed in cell lines with high and low-high liver metastases. The ω-6 PUFAs in the tumor microenvironment are converted into PGE2 that promotes tumor growth by binding to COX-2 in gastric cancer cells, and PGE2 can progressively enhance the proliferation, invasion and neovascularization of gastric cancer cells over the increase of concentration. On the one hand, ω-3 PUFAs can inhibit the activity of COX-2 and reduce the production of PGE2, thereby inhibiting the proliferation, invasion and neovascularization of tumor cells; on the other hand, ω-3 PUFAs can compete with ω-6 PUFAs to bind to COX-1 to produce PGE3, which can significantly inhibit the proliferation, invasion and neovascularization of tumor cells. In addition, after silencing COX-2 gene, ω-6 inhibits the proliferation, invasion and neovascularization of gastric cancer cells. In order to detect the effect of unsaturated fatty acids in tumor microenvironment on gastric cancer neovascularization, we used gastric cancer cells and stromal cells to construct a co-culture system to culture gastric tumor neovascularization in vitro, and detected the effect of gastric cancer cells with different expression of COX-2 on neovascularization. The effect of MKN45 on the neovascularization of HUVEC in COX-2 positive gastric cancer cells was significantly stronger than that in COX-2 negative gastric cancer cells NUGC-4; ω-6 PUFA could promote the neovascularization of COX-2 positive gastric cancer cells, while ω-3 could inhibit the neovascularization of COX-1 positive gastric cancer cells. The above results demonstrated that the effect of ω-3 and ω-6 PUFA on gastric cancer metastasis was mainly achieved by regulating the physiological functions of COX and PGE.ω-6 enhances the metastatic potential energy of gastric cancer cells by being converted into PGE2 that promotes tumor growth after binding to COX-2; ω-3 can inhibit the activity of COX-2 and reduce the production of PGE2 on the one hand, thereby inhibiting the metastatic potential energy of gastric cancer; on the other hand, ω-3 can compete with ω-6 to bind to COX-1 to produce PGE3 so as to inhibit the metastatic potential energy of gastric cancer. Taking PUFA and its intermediate metabolites as interference factors, the in vitro simulation experiment and exploration experiment of tumor internal environment using co-culture system can more objectively and truly reproduce and observe the effect of PUFA on the microenvironment of gastric cancer cells, which plays an irreplaceable important role in understanding the specific growth, invasion and metastasis mechanism of tumor cells, and also lays an important theoretical foundation for the next in vivo experiment and clinical trials.
At present, there are few studies on ω-3 PUFA, ω-6 PUFA and PGE2, 3 in gastric cancer, and the mechanism and clinical significance of the effect of polyunsaturated fatty acids on the occurrence, development and metastasis of gastric cancer remain to be more deeply and comprehensively studied. Through further in vitro and in vivo experiments at a later stage, our team will find a suitable ratio of two fatty acids or a suitable concentration of COX-2 inhibitor, in order to inhibit the invasion and metastasis of tumor cells, and finally provide a new way for clinical prevention and treatment of gastric cancer.